A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Sunitinib (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 20 Jun 2018 Status changed from not yet recruiting to suspended.
- 03 May 2018 Planned initiation date changed from 1 May 2018 to 1 Jun 2018.